Professional
Added to YB: 2024-05-16
Pitch date: 2024-04-10
BIIB [bullish]
Biogen Inc.
-5.27%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally.
Market Cap
$28.7B
Pitch Price
$202.76
Price Target
N/A
Dividend
N/A
EV/EBITDA
8.35
P/E
22.25
EV/Sales
3.15
Sector
Biotechnology
Category
growth
Show full summary:
Patient Capital Management Opportunity Equity New Portfolio Holding: Biogen Inc.
BIIB: New CEO Viehbacher leads turnaround with cost cuts & disciplined investments after Aduhelm fallout. Leqembi Alzheimer's drug has slow uptake but strong long-term potential in underserved market. Attractive valuation for proven biotech with free call option on pipeline & Leqembi launch.
Read full article (1 min)